Literature DB >> 7410535

Influence of thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion: evidence for an additional feedback mechanism in the control of thyroid hormone secretion.

C M Feek, J S Sawers, N S Brown, J Seth, W J Irvine, A D Toft.   

Abstract

Serum TSH and PRL concentrations were measured after the randomized oral administration of either metoclopramide, L-dopa, or placebo on 3 consecutive days to five patients with overt primary hypothyroidism (low serum total T4 and raised serum TSH) and to five patients with subclinical hypothyroidism (normal serum total T4 and raised serum TSH). In both groups there was a rise in serum TSH and PRL concentrations after metoclopramide and a fall after L-dopa when compared with the effect of the placebo. However, the rise in serum TSH and PRL concentrations was significantly greater in patients with subclinical hypothyroidism compared to that in patients with overt hypothyroidism. It was not possible to show any significant difference in the degree of fall of these pituitary hormones after L-dopa administration in the two groups. These results suggest that in addition to the established negative feedback of thyroid hormones at the level of anterior pituitary thyrotropes, there is a previously unrecognized effect of thyroid hormones at the hypothalamus, resulting in increased dopaminergic inhibition of TSH release. Stimulation of hypothalamic dopamine by thyroid hormones also inhibits PRL secretion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7410535     DOI: 10.1210/jcem-51-3-585

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 2.  Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors.

Authors:  S Mohammadi; M Dolatshahi; F Rahmani
Journal:  J Endocrinol Invest       Date:  2020-06-04       Impact factor: 4.256

3.  The TRH induced PRL release in patients with autonomous thyroid nodules before and after surgical treatment.

Authors:  M Langer; C Costanza; A R Casu; S Rassu; G Madeddu
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

Review 4.  Imbalance between thyroid hormones and the dopaminergic system might be central to the pathophysiology of restless legs syndrome: a hypothesis.

Authors:  Jose Carlos Pereira; Marcia Pradella-Hallinan; Hugo de Lins Pessoa
Journal:  Clinics (Sao Paulo)       Date:  2010-05       Impact factor: 2.365

5.  Abnormal daily periodicity of serum thyrotropin (TSH) and evidence for defective TSH suppression in a case of non-neoplastic syndrome of inappropriate TSH secretion.

Authors:  S Benvenga; G A Sobbrio; F Vermiglio; L Li Calzi; S Cannavò; F Consolo; F Trimarchi
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

Review 6.  Neuroendocrine regulation of thyrotropin-releasing hormone (TRH) in the tuberoinfundibular system.

Authors:  R Toni; R M Lechan
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

7.  TRH: pathophysiologic and clinical implications.

Authors:  C R Pickardt; P C Scriba
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

8.  The influence of thyroid disorders on the dopaminergic regulation of prolactin, thyrotropin and growth hormone.

Authors:  P C Eskildsen; C B Kirkegaard
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

9.  Blockade of menstrual cycle by thyroidectomy in Japanese monkeys (Macaca fuscata fuscata).

Authors:  Masumi Nozaki; Keiko Shimizu; Fusako Mitsunaga; Gen Watanabe; Kazuyoshi Taya
Journal:  Endocrine       Date:  2002-11       Impact factor: 3.925

10.  Low Growth Hormone Levels in Short-Stature Children with Pituitary Hyperplasia Secondary to Primary Hypothyroidism.

Authors:  Minghua Liu; Yanyan Hu; Guimei Li; Wenwen Hu
Journal:  Int J Endocrinol       Date:  2015-09-02       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.